Status and phase
Conditions
Treatments
About
Study to investigate microvascular and antiinflammatory effects of Rivaroxaban compared to low dose aspirin in type 2 diabetic patients.
Especially patients with cardiovascular disease and subclinical inflammation are in the focus of interest.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Type 2 diabetes duration between 2 and 20 years
Two or more components of metabolic syndrome:
Or at least one of the following
Increased hsCRP (> 2 mg/l but < 10 mg/l) at or within 6 months prior to screening and/or increased PAI 1 (> 15 ng/ml) at or within 6 months prior to screening (the historical hsCRP or PAI 1 value can be used only if the patient was in stable conditions regarding the concomitant diseases and statin therapy since the time point of measurement)
Stable treatment with statins (if tolerated/clinically indicated)
Age 40 - 75 years
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
179 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal